17 completed, 3 active not recruiting, 3 terminated, 2 not yet recruiting. 9 Phase 1, 9 Phase 3, 4 Phase 2, 4 Phase 4, 1 Not applicable.
Follow selexipag: new trials by email Literature Review of selexipag trials Research Report on selexipag
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Withdrawal of Prostacyclin Pathway Therapy in Patients With Pulmonary Arterial Hypertension Receiving Sotatercept (WATERLOO) Discontinuation of parenteral prostacyclins analogues or selexipag - Pulmonary Arterial Hypertension | Not applicable | Not yet recruiting | University of Alberta | 78 | 2026-10-30 | 2026-09-23 |
| Randomized Study of Triple Therapy vs Sildenafil Dose Optimization in Pulmonary Arterial Hypertension Prostacyclin Pathway Agent, Sildenafil Dose Optimization - Pulmonary Arterial Hypertension (PAH) | Phase 4 | Recruiting | University of Sao Paulo General Hospital | 196 | 2026-07-22 | 2026-07-30 |
| Bioequivalence Study to Compare Selexipag 400 Microgram Film Coated Tablets Versus Uptravi® (Selexipag) 400 Microgram Film Coated Tablets Selexipag Film Coated Tablets (T1), Selexipag Film Coated Tablets (T2), Uptravi® (selexipag) film coated tablets - Arterial Hypertension (PAH) | Phase 1 | Completed | Humanis Saglık Anonim Sirketi | 30 | 2026-04-08 | 2026-07-09 |
| Patient-Reported Outcomes and Adherence After Transition From Inhaled Iloprost to Oral Selexipag in Pulmonary Arterial Hypertension Selexipag - Pulmonary Arterial Hypertension (PAH) | Not yet recruiting | University of Sao Paulo General Hospital | 32 | 2026-03-01 | 2026-02-13 | |
| Bioequivalence Study to Compare Selexipag 400mcg Film Coated Tablets (400 mcg Selexipag) Versus Uptravi® 400mcg Film Coated Tablets (400 mcg Selexipag) Selexipag Film Coated Tablets, Uptravi® Film Coated Tablets - Pulmonary Arterial Hypertension (PAH) | Phase 1 | Completed | Humanis Saglık Anonim Sirketi | 14 | 2025-01-09 | 2025-04-22 |
| Pulmonary Hypertension: Intensification and Personalisation of Combination Rx Selexipag, Riociguat, CardioMEMS pulmonary artery pressure monitor - Pulmonary Arterial Hypertension | Phase 4 | Active not recruiting | Sheffield Teaching Hospitals NHS Foundation Trust | 70 | 2023-06-14 | 2026-08-07 |
| A Study Providing Treatment Access in Participants With Pulmonary Hypertension Completing a Parent Study and Having no Other Option Macitentan, Selexipag, Macitentan/Tadalafil FDC - Hypertension, Pulmonary | Phase 3 | Recruiting | Actelion | 280 | 2022-05-04 | 2026-09-25 |
| A Study of Selexipag Assessing Right Ventricular Remodeling in Pulmonary Arterial Hypertension by Cardiac Magnetic Resonance Imaging JNJ-67896049 - Pulmonary Arterial Hypertension | Phase 4 | Terminated | Actelion | 9 | 2021-07-07 | 2025-03-30 |
| A Study of Selexipag in Participants Who Participated in a Previous Selexipag Study Selexipag - Hypertension, Pulmonary | Phase 3 | Completed | Actelion | 43 | 2021-05-03 | 2025-05-01 |
| A Study in Participants With Sarcoidosis-associated Pulmonary Hypertension (SAPH) to Assess the Efficacy and Safety of Oral Selexipag Selexipag, Placebo - Sarcoidosis-associated Pulmonary Hypertension | Phase 2 | Terminated | Actelion | 10 | 2021-02-26 | 2024-05-08 |
| Selexipag for the Treatment of Schistosomiasis-Associated Pulmonary Arterial Hypertension Selexipag - Pulmonary Hypertension, Schistosomiasis | Phase 2 | Unknown | University of Sao Paulo General Hospital | 20 | 2020-10-15 | 2020-10-19 |
| A Study of Selexipag as Add-On Treatment to Standard of Care in Children With Pulmonary Arterial Hypertension Selexipag, Placebo, Standard of Care (SOC): Endothelin receptor antagonist - Hypertension, Pulmonary | Phase 3 | Active not recruiting | Actelion | 138 | 2020-01-16 | 2026-09-25 |
| A Study to Find Out if Selexipag is Effective and Safe in Patients With Chronic Thromboembolic Pulmonary Hypertension When the Disease is Inoperable or Persistent/Recurrent After Surgery and/or Interventional Treatment Selexipag, Placebo - Chronic Thromboembolic Pulmonary Hypertension | Phase 3 | Terminated | Actelion | 128 | 2019-01-23 | 2024-06-21 |
| A Clinical Study of to Confirm the Doses of Selexipag in Children With Pulmonary Arterial Hypertension selexipag (Uptravi) - Pulmonary Arterial Hypertension | Phase 2 | Active not recruiting | Actelion | 63 | 2018-07-23 | 2026-09-25 |
| A Clinical Study to Assess the Effect of Clopidogrel on the Pharmacokinetics of Selexipag and Its Active Metabolite in Healthy Male Subjects Selexipag, Clopidogrel - Healthy Subjects | Phase 1 | Completed | Actelion | 22 | 2018-03-05 | 2025-06-22 |
| Safety Study of the Switch From Oral Selexipag to Intravenous Selexipag in Subjects With Stable Pulmonary Arterial Hypertension i.v. selexipag, oral selexipag (Uptravi) - Pulmonary Arterial Hypertension | Phase 3 | Completed | Actelion | 20 | 2017-12-04 | 2025-06-29 |
| Effect of Selexipag on Daily Life Physical Activity of Patients With Pulmonary Arterial Hypertension. Selexipag, Placebo - Pulmonary Arterial Hypertension | Phase 4 | Completed | Actelion | 108 | 2017-11-08 | 2025-03-30 |
| Potential Pharmacokinetic Interaction Between Selexipag and Midazolam in Healthy Male Subjects Midazolam, Selexipag - Healthy Subjects | Phase 1 | Completed | Actelion | 20 | 2016-07-01 | 2016-10-13 |
| A Clinical Study to Investigate the Effect of Gemfibrozil or Rifampicin on Blood Concentrations of Selexipag in Healthy Subjects Selexipag, Gemfibrozil, Rifampicin - Healthy Subjects | Phase 1 | Completed | Actelion | 40 | 2016-06-01 | 2025-02-03 |
| Comparison of Two Dose Strengths of Selexipag in Healthy Adults Selexipag (adult formulation), Selexipag (pediatric formulation) - Healthy Subjects | Phase 1 | Completed | Actelion | 20 | 2016-06-01 | 2025-02-03 |
Showing 20 of 29. Sign in to see all of them.
Pulmonary Arterial Hypertension (15) · Hypertension, Pulmonary (5) · Hypertension (1) · Motor Activity (1) · Raynaud Disease (1) · Sarcoidosis (1) · Schistosomiasis (1) · Scleroderma, Systemic (1) · Thromboangiitis Obliterans (1) · Treatment Adherence and Compliance (1)
Actelion (22) · University of Sao Paulo General Hospital (3) · Humanis Saglık Anonim Sirketi (2) · Sheffield Teaching Hospitals NHS Foundation Trust (1) · University of Alberta (1)
United States (12) · Germany (11) · France (10) · United Kingdom (10) · Belgium (9) · Canada (8) · Russia (7) · South Korea (7) · Taiwan (7) · Ukraine (7) · Belarus (6) · Brazil (6) · China (6) · Hungary (6) · Israel (6)
Aline Frey (2) · Alexander Rothman, MD / PhD (1) · Caio Fernandes (1) · Caio Fernandes, MD (1) · Caio J Fernandes, PHD (1) · Catherine Boisson (1) · Daniela Baldoni, PhD, PharmD (1) · Dr. Jason Weatherald, MD, MSc, FRCPC (1) · Julian Borissoff, MD, PhD (1) · Margaux Boehler (1) · Matthias Hoch, PhD (1) · Pierre-Eric Juif, PhD (1) · Priska Kaufmann, PhD (1)
PMID 34727317, PMID 24392948, PMID 26699168, PMID 27885399, PMID 28556581, PMID 28639216, PMID 28715853, PMID 28818881, PMID 29193819, PMID 29307087, PMID 29447737, PMID 30391194, PMID 30982349, PMID 32415684, PMID 33536021, PMID 33545163, PMID 34593120, PMID 36089068, PMID 39222737, PMID 39326918, PMID 40433632, PMID 41429287
2016 (3), 2018 (2), 2019 (2), 2009 (1), 2023 (1)